Investing.com - Chinook Therapeutics (NASDAQ: KDNY) reported first quarter EPS of $-0.85, $0.06 worse than the analyst estimate of $-0.79. Revenue for the quarter came in at $1.83M versus the consensus estimate of $300K.
Chinook Therapeutics's stock price closed at $21.52. It is down -10.82% in the last 3 months and up 55.16% in the last 12 months.
Chinook Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Chinook Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Chinook Therapeutics's Financial Health score is "fair performance".
Check out Chinook Therapeutics's recent earnings performance, and Chinook Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar